Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: TBC
Search results
628 results
-
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Brolucizumab for treating wet age-related macular degeneration [ID1254]
In development [GID-TA10455] Expected publication date: 03 February 2021
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]
In development [GID-TA10485] Expected publication date: 23 June 2021
-
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]
In development [GID-TA10670] Expected publication date: TBC
-
AR101 for treating peanut allergy [ID1282]
In development [GID-TA10713] Expected publication date: TBC
-
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680]
In development [GID-TA10551] Expected publication date: 10 February 2021
-
Pegcetacoplan for previously treated paroxysmal nocturnal haemoglobinuria [ID3746]
In development [GID-TA10651] Expected publication date: 02 February 2022
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Filgotinib for treating moderate to severe rheumatoid arthritis ID1632
In development [GID-TA10541] Expected publication date: 24 February 2021
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: 21 April 2021
-
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]
In development [GID-TA10498] Expected publication date: 13 October 2021
-
Cenobamate for focal onset seizures in epilepsy [ID1553]
In development [GID-TA10661] Expected publication date: 13 October 2021
-
Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]
In development [GID-TA10639] Expected publication date: TBC
-
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development [GID-TA10606] Expected publication date: 08 June 2022
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]
In development [GID-TA10630] Expected publication date: 23 March 2022
-
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]
In development [GID-TA10299] Expected publication date: TBC
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Pancreatic cancer - capecitabine [ID389]
In development [GID-TAG394] Expected publication date: TBC
-
Melanoma (advanced and metastatic) - temozolomide [ID316]
In development [GID-TAG401] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
In development [GID-TAG406] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: 01 October 2014
-
Prostate cancer (prevention) - dutasteride [ID75]
In development [GID-TAG409] Expected publication date: TBC
-
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
In development [GID-TAG411] Expected publication date: TBC
-
Obesity - lorcaserin [ID337]
In development [GID-TAG420] Expected publication date: TBC
-
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]
In development [GID-TAG369] Expected publication date: TBC
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
In development [GID-TAG372] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Prostate cancer - intensity modulated radiotherapy [ID17]
In development [GID-TAG396] Expected publication date: TBC
-
Colon cancer (adjuvant) - irinotecan [ID379]
In development [GID-TAG380] Expected publication date: TBC
-
Head and neck cancer - contusugene ladenovec [ID76]
In development [GID-TAG407] Expected publication date: TBC
-
Lung cancer (non-small cell) - afatinib [ID357]
In development [GID-TAG422] Expected publication date: TBC
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
In development [GID-TAG330] Expected publication date: TBC
-
Prostate cancer (hormone refractory) - atrasentan [ID390]
In development [GID-TAG379] Expected publication date: TBC
-
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
In development [GID-TAG300] Expected publication date: TBC
-
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]
In development [GID-TAG440] Expected publication date: TBC
-
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]
In development [GID-TAG410] Expected publication date: TBC
-
Clostridium difficile associated diarrhoea - tolevamer [ID378]
In development [GID-TAG389] Expected publication date: TBC
-
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]
In development [GID-TAG405] Expected publication date: TBC
-
Heart failure (acute decompensated) - nesiritide [ID384]
In development [GID-TAG376] Expected publication date: TBC
-
Atrial fibrillation - idraparinux sodium [ID375]
In development [GID-TAG383] Expected publication date: TBC
-
Venous thromboembolism (recurrent) - idraparinux sodium [ID395]
In development [GID-TAG384] Expected publication date: TBC
-
Psoriatic arthritis (moderate to severe) - leflunomide [ID391]
In development [GID-TAG385] Expected publication date: TBC
-
Diabetic retinopathy - ruboxistaurin [ID382]
In development [GID-TAG386] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
In development [GID-TAG388] Expected publication date: TBC
-
Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]
In development [GID-TAG391] Expected publication date: TBC